Development of a high performance (188)W/(188)Re generator by using a synthetic alumina

Progress of energy-related radiochemistry and radionuclide production in the Republic of Korea

The field of radiochemistry in the Republic of Korea has expanded greatly over the last three decades to meet the rapid growth of technological demands in various areas such as nuclear energy and nuclear technologies for human health and environmental protection. Major research activities, which were initially centered at the Korea Atomic Energy Research Institute (KAERI), have gradually spread to major universities and the commercial sector. In this review, progress and recent research trends in nuclear and radiochemistry in Korea are summarized. The main research outcomes achieved by KAERI scientists are highlighted, with emphasis on basic actinide chemistry in nuclear fuel cycles, the radioanalytical chemistry of various radionuclides from radioactive waste and the environment, and medical radionuclide production. In addition, recent efforts to promote radiochemical education and future perspectives are briefly outlined.

Mechanochemically synthesized mesoporous alumina: a smart new-generation sorbent for preparation of chromatographic 188W/188Re generator

Abstract

In an effort towards affordable availability of chromatographic 188W/188Re generators for widespread clinical use, we report the mechanochemical synthesis of mesoporous alumina as an advanced sorbent material for preparation of the generator. The synthesized material exhibits remarkably high sorption capacity (550 ± 12 mg W/g), which is adequate for preparation of clinical-scale generators using low specific activity (LSA) 188W produced in medium flux research reactors. Sorption of 188W in mesoporous alumina follows Freundlich adsorption isotherm and pseudo second order kinetics, indicating that the process is chemisorption. A clinical-scale (~ 14.0 GBq) 188W/188Re generator was developed and its performance was evaluated over a period of 6 months. Rhenium-188 could be consistently obtained from the generator with high yield (> 80%) and it met all the requirements for clinical use. The present strategy is expected to increase the scope of separation chemistry for availing clinical-grade 188Re for the benefit of millions of cancer patients world over.

Graphic abstract

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives

Rhenium-188 (¹⁸⁸Re) is a high energy beta-emitting radioisotope with a short 16.9 h physical half-life, which has been shown to be a very attractive candidate for use in therapeutic nuclear medicine. The high beta emission has an average energy of 784 keV and a maximum energy of 2.12 MeV, sufficient to penetrate and destroy targeted abnormal tissues. In addition, the low-abundant gamma emission of 155 keV (15%) is efficient for imaging and for dosimetric calculations. These key characteristics identify ¹⁸⁸Re as an important therapeutic radioisotope for routine clinical use. Moreover, the highly reproducible on-demand availability of ¹⁸⁸Re from the ¹⁸⁸W/¹⁸⁸Re generator system is an important feature and permits installation in hospital-based or central radiopharmacies for cost-effective availability of no-carrier-added (NCA) ¹⁸⁸Re. Rhenium-188 and technetium-99 m exhibit similar chemical properties and represent a “theranostic pair.” Thus, preparation and targeting of ¹⁸⁸Re agents for therapy is similar to imaging agents prepared with ^99mTc, the most commonly used diagnostic radionuclide. Over the last three decades, radiopharmaceuticals based on ¹⁸⁸Re-labeled small molecules, including peptides, antibodies, Lipiodol and particulates have been reported. The successful application of these ¹⁸⁸Re-labeled therapeutic radiopharmaceuticals has been reported in multiple early phase clinical trials for the management of various primary tumors, bone metastasis, rheumatoid arthritis, and endocoronary interventions. This article reviews the use of ¹⁸⁸Re-radiopharmaceuticals which have been investigated in patients for cancer treatment, demonstrating that ¹⁸⁸Re represents a cost effective alternative for routine clinical use in comparison to more expensive and/or less readily available therapeutic radioisotopes.

Preparation and characterization of zirconium silico188W-tungstate as a base material for 188W/188Re generator

Zr:W:Si. The optimum gel was prepared using the molar ratio 1:1:7 at pH 8. The ZrSiW gel was investigated by FTIR, XRD, thermal analysis (TGA and DTA), FESEM, XRF, and NAA. Then, XRF and NAA techniques were used to estimate the proportion of the constituents of the gel according to the molecular formula [ZrO₂(Si(WO₄)₂)16H₂O]. ¹⁸⁸W/¹⁸⁸Re generator was prepared based on the selected ZrSi¹⁸⁸W gel, which gives the highest tungsten content (393.3 mg W/g gel) with 75 ± 3% elution yield of ¹⁸⁸Re. Quality control was studied on the ¹⁸⁸Re to make sure its validity for clinical applications.

Development of an electrochemical 188W/188Re generator as a technique for separation and purification of 188Re in radiopharmaceutical applications

In this study, a simple electrochemical procedure adaptable for using low specific activity ¹⁸⁸W for separation and purification of ¹⁸⁸Re from ¹⁸⁸W to obtain no carrier added (NCA) ¹⁸⁸Re is developed. The electrochemical parameters were optimized to maximize the ¹⁸⁸Re electrodeposition yield with minimal ¹⁸⁸W contamination. Two cycle electrolysis procedure was developed. The first electrochemical cell was used for separation of ¹⁸⁸Re and in the second electrochemical cell, separation and purification of ¹⁸⁸Re with >90% deposition yield of ¹⁸⁸Re and minimal contamination of ¹⁸⁸W (<10^-4%) was achieved. The overall electrodeposition yield of ¹⁸⁸Re was >90% with >99% radionuclidic purity and >99% radiochemical purity suitable for radiopharmaceutical applications. Furthermore, the performance of the generator remained consistent during a period of 69 days, one half-life of ¹⁸⁸W, when the electrochemical separation procedure was performed frequently, at least once in 5 days.

An overview of radioisotope separation technologies for development of 188W/188Re radionuclide generators providing 188Re to meet future research and clinical demands

Separation technologies for ¹⁸⁸W/¹⁸⁸Re radionuclide generators.